Skip to content

A study for safety of excessive intake of supplements Open-label study

A study for safety of excessive intake of supplements Open-label study - A study for safety of excessive intake of supplements

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000043616
Enrollment
15
Registered
2021-03-15
Start date
2021-03-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy individuals

Interventions

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Subjects of men and women aged 20 to 64 (2) Subjects with a BMI of less than 30 kg / m2 (3) Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing.

Exclusion criteria

Exclusion criteria: (1) Persons with a history of liver disease, renal disease, digestive system disease, heart disease, diabetes, or other diseases that may affect the results of this study, or subjects with a history of surgery (2) Subjects with abnormal liver function and renal function test values (3) Subjects with diseases currently being treated (4) Subjects with food and drug allergies (5) Subjects with anemia symptoms (6) Subjects who play intense sports and subjects who are on a diet (7) Subjects who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period (8) Subjects who are continuously treated with medicines (including OTC and prescription drugs) (9) Subjects who are excessively ingesting alcohol (10) Subjects who cannot stop drinking from the day before the test to the day of the test (11) Pregnant subjects or subjects who are planning to become pregnant or breastfeed during the test period (12) Subjects who are participating in or will participate in other clinical trials at the start of this study. (13) Other subjects judged by the investigator to be inappropriate

Design outcomes

Primary

MeasureTime frame
Adverse event Physical examination Hematological test Blood biochemical test Urinalysis

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness Support Co., Ltd. Clinical Trial Division

mterashima@oneness-sup.co.jp0648018917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026